Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 385

Sort by

Sort Order Select

Journal Articles

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Blood (2019) 134 (26): 2388–2398.

https://doi.org/10.1182/blood.2019001385

Published: 2019

Includes: Supplemental data

Journal Articles

Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies

Roger Belizaire, MD PhD, Sebastian Koochaki, BS, MS, Namrata Udeshi, PhD, Alexis Vedder, BS, Lei Sun, Monica Schenone, PhD, Steven Carr, PhD, Eric Padron, MD, Benjamin L. Ebert, MD PhD

Blood (2019) 134 (Supplement_1): 563.

https://doi.org/10.1182/blood-2019-122503

Published: 2019

Journal Articles

A Novel Role for HMGN1 in Down Syndrome Acute Lymphoblastic Leukemia

Elyse C Page, BSc, Susan L Heatley, PhD MD, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Paul Q Thomas, PhD, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 1462.

https://doi.org/10.1182/blood-2019-126244

Published: 2019

Journal Articles

Immune Monitoring of CD34+ Placental Cell Derived Natural Killer Cell Therapy (PNK-007) in Phase I Study of Multiple Myeloma

William Van Der Touw, Lin Kang, PhD, Joseph Dennis Tario, PhD, Bhavani Stout, Vanessa Voskinarian-Berse, Valentina Rousseva, Paul K. Wallace, MS, PhD, Robert Hariri, MD PhD, Xiaokui Zhang, PhD

Blood (2019) 134 (Supplement_1): 4457.

https://doi.org/10.1182/blood-2019-124509

Published: 2019

Journal Articles

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Tengteng Yu, MD PhD, Liang Lin, PhD, Kenneth Wen, Lijie Xing, MD, Jiye Liu, PhD, Shih-Feng Cho, MD PhD, Phillip Hsieh, Ola Rizq, MD PhD, Yuyin Li, PhD, Liang Yu, Xiang Wu, Eugenio Morelli, MD, Yan Xu, MD, Gang An, MD, Nikhil C. Munshi, MD, Lugui Qiu, MD PhD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4371.

https://doi.org/10.1182/blood-2019-127454

Published: 2019

Journal Articles

Leptin Receptor As a Functional Marker for Long-Term Repopulating Hematopoietic Stem Cells

Thao Trinh, BS, Scott Cooper, MS, Arafat Aljoufi, MD, Edward F. Srour, PhD, Hal E. Broxmeyer, PhD

Blood (2019) 134 (Supplement_1): 3712.

https://doi.org/10.1182/blood-2019-128659

Published: 2019

Journal Articles

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

David Cella, PhD, Ellen K. Ritchie, MD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3850.

https://doi.org/10.1182/blood-2019-123790

Published: 2019

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

https://doi.org/10.1182/blood-2019-130290

Published: 2019

Journal Articles

RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms

Garima Pandey, Nathan Horvat, Narmin E. Amin, Afua A. Akuffo, Christelle Colin, Pearlie K. Epling-Burnette, Gary W. Reuther

Blood (2019) 134 (Supplement_1): 4198.

https://doi.org/10.1182/blood-2019-128937

Published: 2019

Journal Articles

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Lai N Chan, PhD, Mark A. Murakami, MDMA,MMSc, Rebecca Caesar, Christian Hurtz, PhD, Kohei Kume, PhD, Teresa Sadras, PhD, Seyedmehdi Shojaee, PhD, Petri Pölönen, MSc, Amol Ugale, PhD, Jaewoong Lee, PhD, Kadriye Nehir Cosgun, PhD, Huimin Geng, PhD, Merja Heinäniemi, PhD, Olli Lohi, MD PhD, Arun P. Wiita, MD PhD, Shai Izraeli, MD, David M Weinstock, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 3944.

https://doi.org/10.1182/blood-2019-130774

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

En-Abl-ing treatment of “Ph-like” ALL?

Adele K. Fielding

Blood (2019) 134 (16): 1277–1278.

https://doi.org/10.1182/blood.2019002621

Published: 2019

Journal Articles

The BRISC deubiquitinating enzyme complex limits hematopoietic stem cell expansion by regulating JAK2 K63-ubiquitination

Ryan Donaghy, Xu Han, Krasimira Rozenova, Kaosheng Lv, Qinqin Jiang, Miriam Doepner, Roger A. Greenberg, Wei Tong

Blood (2019) 133 (14): 1560–1571.

https://doi.org/10.1182/blood-2018-10-877563

Published: 2019

Includes: Supplemental data

Journal Articles

Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma

Linda von Hoff, Eva Kärgel, Vedran Franke, Erik McShane, Kathrin W. Schulz-Beiss, Giannino Patone, Nikolai Schleussner, Marina Kolesnichenko, Norbert Hübner, Oliver Daumke, Matthias Selbach, Altuna Akalin, Stephan Mathas, Claus Scheidereit

Blood (2019) 133 (13): 1489–1494.

https://doi.org/10.1182/blood-2018-08-871293

Published: 2019

Includes: Supplemental data

Journal Articles

C/Ebpg (CCAAT/Enhancer Binding Protein Gamma) Balances Cytotoxic and Secretory Potential of Natural Killer Cells

Izabela Aparecida Lopes, MSc, Miroslava Kardosova, MSc, Thiago Mantello Bianco, MSc, Adriana Queiroz Arantes, MD, Cleide Araújo Silva, MSc, Priscila Santos Scheucher, PhD, Daniel G. Tenen, MD, Sanghoon Lee, PhD, Eduardo Magalhães Rego, MD PhD, Robert S. Welner, PhD, Meritxell Alberich-Jorda, Lorena Lobo Figueiredo-Pontes, MD PhD

Blood (2018) 132 (Supplement 1): 3721.

https://doi.org/10.1182/blood-2018-99-119389

Published: 2018

Journal Articles

High-Dose TSLP Induces Co-Receptor Internalization and Signal Shutdown in Ph-like B-ALL with Overexpression of CRLF2

WayAnne B. Watson, Hossam Alkashgari, MD, Cornelia Stoian, PhD, Jacqueline S. Coats, Ineavely Baez, Hannah Choi, Benjamin Becerra, DrPH, Rishikesh Chavan, MD, Muhammad Omair Kamal, MD, Shadi Farzin Gohar, MD, Xianmei Meng, PhD, Sinisa Dovat, MD PhD, Kimberly J. Payne, PhD, Hoda Erjaee, DVM, PhD

Blood (2018) 132 (Supplement 1): 4024.

https://doi.org/10.1182/blood-2018-99-114336

Published: 2018

Journal Articles

Different Classes of ABL1 Fusions Activate Different Downstream Signalling Nodes

Lauren M Brown, BSc, Hannah Huckstep, BSc, Jarrod Sandow, PhD, Ray C Bartolo, PhD, Nadia Davidson, PhD, Breon Schmidt, BSc, Stefan Bjelosevic, BSc, Ricky W Johnstone, PhD, Alicia Oshlack, PhD, Melissa Davis, PhD, Paul G Ekert

Blood (2018) 132 (Supplement 1): 2628.

https://doi.org/10.1182/blood-2018-99-117844

Published: 2018

Journal Articles

Gene Editing of BTK in Acute Myeloid Leukaemia Using CRISPR-Cas9

Melanie Maerken, MS, BSc, David MacEwan, PhD, Nicholas Harper, PhD, Joseph R Slupsky, PhD, Adam Linley, PhD

Blood (2018) 132 (Supplement 1): 3952.

https://doi.org/10.1182/blood-2018-99-113804

Published: 2018

Journal Articles

Successful of Chemo-Free Treatment with Dasatinib and Blinatumomab in a Pediatric EBF1-PDGFRβ Positive Acute Lymphoblastic Leukemia

Fara Petruzziello, MD, Giovanna Giagnuolo, MD, Giovanni Cazzaniga, PhD, Giuliana Beneduce, MD, Franco Locatelli, Pio Stellato, MD, Grazia Fazio, PhD, Giuseppe Mirabelli, PhD, Giuseppe Menna, MD, Rosanna Parasole, MD

Blood (2018) 132 (Supplement 1): 5213.

https://doi.org/10.1182/blood-2018-99-113829

Published: 2018

Journal Articles

Mechanism of Synergistic Effects on T Cell Activation By Avadomide (CC-122) and Nivolumab

Yumi Nakayama, PhD, Matthew E. Stokes, PhD, Michelle Waldman, MS, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD

Blood (2018) 132 (Supplement 1): 4133.

https://doi.org/10.1182/blood-2018-99-114469

Published: 2018

NARROW

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies

A Novel Role for HMGN1 in Down Syndrome Acute Lymphoblastic Leukemia

Immune Monitoring of CD34+ Placental Cell Derived Natural Killer Cell Therapy (PNK-007) in Phase I Study of Multiple Myeloma

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Leptin Receptor As a Functional Marker for Long-Term Repopulating Hematopoietic Stem Cells

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

En-Abl-ing treatment of “Ph-like” ALL?

The BRISC deubiquitinating enzyme complex limits hematopoietic stem cell expansion by regulating JAK2 K63-ubiquitination

Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma

C/Ebpg (CCAAT/Enhancer Binding Protein Gamma) Balances Cytotoxic and Secretory Potential of Natural Killer Cells

High-Dose TSLP Induces Co-Receptor Internalization and Signal Shutdown in Ph-like B-ALL with Overexpression of CRLF2

Different Classes of ABL1 Fusions Activate Different Downstream Signalling Nodes

Gene Editing of BTK in Acute Myeloid Leukaemia Using CRISPR-Cas9

Successful of Chemo-Free Treatment with Dasatinib and Blinatumomab in a Pediatric EBF1-PDGFRβ Positive Acute Lymphoblastic Leukemia

Mechanism of Synergistic Effects on T Cell Activation By Avadomide (CC-122) and Nivolumab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only